Klin Farmakol Farm. 2018;32(4):21-31 | DOI: 10.36290/far.2018.025

Drug-induced lung injury

Vladimíra Lošťáková1, Milan Kuna2, Vítězslav Kolek1, Filip Čtvrtlík3, Gabriela Vaculová2
1 Klinika plicních nemocí a tuberkulózy FN a LF UP Olomouc
2 Oddělení klinické farmacie, Lékárna FN Olomouc
3 Radiologická klinika FN Olomouc

The treatment of various types of diseases can be associated with a number of adverse side effects of drugs. Drugs that can cause lungdisease are constantly on the increase. This is due to not only the development of new drugs, but also the use of modern diagnosticmeans allowing more accurate investigation. The mainstay of diagnosing drug-induced injury is the identification of a drug that, withcertain probability, could have induced lung injury. To identify it among other drugs that a patient is taking as well as to distinguishdrug-induced injury from a possible exacerbation of an existing lung disease is difficult. The most common drugs that cause injury tothe lung parenchyma include amiodarone, cytostatic drugs, immunosuppressants, antibiotics, and those used for biological therapyof systemic diseases or tumours. Drug-induced lung injury may follow an acute or subacute/chronic course. It is usually reversible afterwithdrawal of the causal drug or with timely initiation of treatment. The complaints do not differ from those in other lung diseases(cough, sometimes with coughing up of blood; breathing difficulties; shortness of breath; and chest pain). Neither clinical types norradiological or pathological changes suggestive of a specific phenotype of drug-induced injury are known. Most commonly, there isapparent interstitial involvement with various phenotypes of interstitial pulmonary processes (IPP). However, drug-induced lung injurymay even lead to airway or pleural disease. A list of drugs that represent a risk of lung disease is available at www.pneumotox.com.

Keywords: drug‑induced
lung injury, mechanism of drug action, risk factors, diagnosis, phenotypes of interstitial lung disorder

Published: January 1, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Lošťáková V, Kuna M, Kolek V, Čtvrtlík F, Vaculová G. Drug-induced lung injury. Klin Farmakol Farm. 2018;32(4):21-31. doi: 10.36290/far.2018.025.
Download citation

References

  1. Allen JN. Drug-induced eosinophilic lung disease. Clin Chest Med. 2004; 25(1): 77-88. Go to original source... Go to PubMed...
  2. Carnovale C, Pellegrino P, Perrone V, et al. Establishing the correlation between statins and cough: case series report and analysis of adverse drug reactions in the international databases. Eur J Clin Pharmacol. 2014; 70(12): 1529-1531. Go to original source... Go to PubMed...
  3. Costabel U. Atlas der bronchoalveolären Lavage. Thieme. 1994; 42-48.
  4. Česká pneumologická a ftizeologická společnost ČLS JEP. Guidelines. [cit. 1. 10. 2018]. Dostupné na: http://www.pneumologie.cz
  5. Fernández AB, Karas RH, Alsheikh-Ali AA. Statins and interstitial lung disease: a systematic review of the literature and of food and drug administration adverse event reports. Chest. 2008; 134(4): 824-830. Go to original source... Go to PubMed...
  6. Guzman J, Costabel U. Die bronchoalveoläre Lavage. Verh. dtsch. Ges. Zytol. 1991; 22-34.
  7. Homolka J, Votava V. Intersticiální plicní procesy. Maxdorf. 1999; 100-108.
  8. Klapholz L, Leitersdorf E, Weinrauch L. Leucocytoclastic vasculitis and pneumonitis induced by metformin. Br Med J (Clin Res Ed). 1986; 293(6545): 483. Go to original source... Go to PubMed...
  9. Kolek V, Kašák V, et al. Pneumologie. Maxdorf. 2010; 238-239.
  10. Kolek V. Doporučené postupy v pneumologii. Maxdorf, Praha. 2016; 564.
  11. Kono M, Hirota K, Yokoe A. Wandering pneumonia caused by dabigatran. Intern Med. 2014; 53(16): 1825-1827. Go to original source... Go to PubMed...
  12. Kubo K, Azuma A, Kanazawa M, et al. Consensus statement for the diagnosis and treatment of drug-induced lung injuries. Respir Investig. 2013; 51(4): 260-277. Go to original source... Go to PubMed...
  13. Lošťáková V. Význam cytologie v pneumologii. Lékařské listy. 2006; 32-33.
  14. Meira Dias O, Guedes Baldi B, Nathan Costa A, et al. Interstitial lung disease with statin-associated necrotizing autoimmune myopathy responding to rituximab. Arch Bronconeumol. 2016; 52(7): 395-397. Go to original source...
  15. Papiris SA, Triantafillidou C, Kolilekas, et al. Amiodarone: review of pulmonary effects and toxicity. Drug Saf. 2010; 33(7): 539-558. Go to original source... Go to PubMed...
  16. Pneumotox online: the drug-induced lung diseases. [cit. 1. 10. 2018]. Dostupné na: https://www.pneumotox.com/drug/index/?page=10
  17. Skeoch S, Weatherley N, Swift AJ, et al. Drug-Induced Interstitial Lung Disease: A Systematic Review. J Clin Med. 2018; 7(10). Go to original source...
  18. Skřičková J. Komentář ke článku Schreiber, et al. Poléková onemocnění plic. Medicína po promoci. 2011.
  19. Spagnolo P, Richeld R, Raghu G. The role of bronchoalveolar lavage cellular analysis in the diagnosis of interstitial lung diseases. Eur. Respir. Mon. 2009; 4: 36-47. Go to original source...
  20. SÚKL. Legislativní požadavky. [cit. 1. 10. 2018]. Dostupné na: http://www.sukl.cz/leciva/legislativni-pozadavky
  21. SÚKL. Databáze léků. [cit. 1. 10. 2018]. Dostupné na: http://www.sukl.cz/modules/medication/search.php
  22. Šimeček C. Cytologická vyšetření v pneumologii. Státní zdravotnické nakladatelství, Praha. 1963; 205.
  23. Tomari S, Homma K, Noguchi T, et al. Development of Interstitial Lung Disease after Initiation of Apixaban Anticoagulation Therapy. J Stroke Cerebrovasc, DiS. 2016; 25(7): 1767-1769. Go to original source... Go to PubMed...
  24. Vašáková M, Polák J, Matěj R. Intersticiální plicní procesy. Maxdorf. 2016; 279-290.
  25. Wells AU. The clinical utility of bronchoalveolar lavage in diffuse parenchymal lung disease. Eur Respir Rev. 2010; 19(117): 237-241. Go to original source... Go to PubMed...
  26. Yanagihara T, Yamamoto N, Kotetsu Y, et al. Interstitial pneumonia caused by dabigatran. Respir Med Case Rep. 2017; 23: 10-12. Go to original source...
  27. Zuccarini G, Bocchino M, Assante LR. Metformin/glibenclamide-related interstitial lung disease: a case report. Sarcoidosis Vasc Diffuse Lung, DiS. 2014; 31(2): 170-173. Go to PubMed...




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.